Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer

Interventional

Phase not listed

Moffitt Cancer Center

The purpose of the study is to examine the feasibility and acceptability of an exercise and nutrition "prehabilitation" program for patients preparing for pancreatic cancer resection (removal).

Treatment Category

Behavioral

Required Mutations

None

Trial Started

2024-02-09

Last Updated by Sponsor

2025-11-14

Estimated Completion

2026-08-01

Eligibility

Inclusion Criteria

* Age 18 years or older

* Biopsy-proven pancreatic ductal adenocarcinoma (PDAC), borderline resectable at diagnosis

* Eastern Cooperative Oncology Group (ECOG) performance status 0-2

* Undergoing neoadjuvant chemotherapy with treatment plan including chemoradiation therapy and surgical resection

* Ability to read and speak English

Exclusion Criteria

* Regular engagement in RT (2x/week targeting all major muscle groups)

* Screen failure for exercise safety based on PAR-Q

* Underlying unstable cardiac or pulmonary disease or symptomatic cardiac disease

* Recent fracture or acute musculoskeletal injury that precludes ability to participate in RT

* Numeric pain rating scale greater than or equal to a 7 out of 10

* Myopathic or rheumatologic disease that impacts physical function

Do you think this trial is incorrectly appearing?

Design Details

AllocationRandomized

Intervention ModelParallel Assignment

MaskingNone (Open Label)

Number to Enroll26

Arms & Interventions

Arms

Interventions

Type: Experimental

Description:

Interventions:

Physical Activity
Nutrition Counseling
Resistance Training

Outcome Measures

Primary Outcome Measures

Feasibility and acceptability of PA/N and RT/N programsUp to 16 weeks

The number of participants who complete T1 and T0 measures.

Secondary Outcome Measures

Examine exploratory outcomes and clinical characteristicsUp to 16 weeks

The number of participants who demonstrate improvements in exploratory outcome measures.

Compare clinical and treatment outcomesUp to 16 weeks

Chi-Square testing will be used to determine if there's a significant difference in outcomes between the treatment group and a usual care comparison group.